KLK3 and prostate carcinoma: Although 10-year data with a larger patient population are desirable to establish long-term efficacy, the fact that an “ablation” median PSA nadir level was obtained at a minimum post-SBRT follow-up interval of 5-years suggests that the DFS result will be durable and competitive with any other local prostate cancer treatment method described to date.